Literature DB >> 22295130

Improving outcomes in cholangiocarcinomas.

Charles Imber, Justin Stebbing, Arjun Shankar.   

Abstract

Entities:  

Year:  2011        PMID： 22295130      PMCID： PMC3269149     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  15 in total

1.  Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience.

Authors:  M F Gerhards; T M van Gulik; L T de Wit; H Obertop; D J Gouma
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

2.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

Authors:  D J Sargent; D Niedzwiecki; M J O'Connell; R L Schilsky
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

3.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

4.  Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.

Authors:  Fumito Ito; Rashmi Agni; Robert J Rettammel; Mark J Been; Clifford S Cho; David M Mahvi; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

5.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

6.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

7.  Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality.

Authors:  Peter Neuhaus; Sven Jonas; Utz Settmacher; Armin Thelen; Christoph Benckert; Enrique Lopez-Hänninen; Rainer E Hintze
Journal:  Langenbecks Arch Surg       Date:  2003-06-18       Impact factor: 3.445

8.  Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience.

Authors:  Tsuyoshi Igami; Hideki Nishio; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Yuji Nimura; Masato Nagino
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-06       Impact factor: 7.027

9.  Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study.

Authors:  Satoshi Kondo; Satoshi Hirano; Yoshiyasu Ambo; Eiichi Tanaka; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

10.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.

Authors:  J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640
View more
  1 in total

Review 1.  Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.

Authors:  Andrew Kuei; Sammy Saab; Sung-Ki Cho; Stephen T Kee; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.